Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy.

Dolezel M, Odrazka K, Vanasek J, Vaculikova M, Vlkova-Sefrova J, Jansa J, Macingova Z, Brodak M, Hartmann I, Melichar B.

J BUON. 2013 Oct-Dec;18(4):949-53.

PMID:
24344022
2.

Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients.

Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):346-51. doi: 10.1038/pcan.2013.26. Epub 2013 Aug 13.

PMID:
23939133
3.

Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.

Alexander AS, Mydin A, Jones SO, Christie J, Lim JT, Truong PT, Ludgate CM.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e713-9. doi: 10.1016/j.ijrobp.2010.11.068. Epub 2011 Jan 27.

PMID:
21277102
4.

Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.

Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Yamada Y, Fidaleo A, Sperling D, Happersett L, Zhang Z.

Eur Urol. 2011 Dec;60(6):1133-9. doi: 10.1016/j.eururo.2011.08.029. Epub 2011 Aug 22.

5.

Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

Alexander A, Crook J, Jones S, Malone S, Bowen J, Truong P, Pai H, Ludgate C.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):23-30. doi: 10.1016/j.ijrobp.2009.01.030. Epub .

PMID:
19395187
6.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
7.

PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.

McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e39-46. doi: 10.1016/j.ijrobp.2012.08.036. Epub 2012 Oct 23.

8.

Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.

Zelefsky MJ, Gomez DR, Polkinghorn WR, Pei X, Kollmeier M.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):529-33. doi: 10.1016/j.ijrobp.2013.02.004. Epub 2013 Mar 21.

PMID:
23523323
9.
10.

Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy.

Mitchell DM, McAleese J, Park RM, Stewart DP, Stranex S, Eakin RL, Houston RF, O'Sullivan JM.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1467-71. Epub 2007 Aug 8.

PMID:
17689886
11.

Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.

McGivern U, Mitchell DM, McDowell C, O'Hare J, Corey G, O'Sullivan JM.

Clin Genitourin Cancer. 2012 Sep;10(3):190-5. doi: 10.1016/j.clgc.2012.04.003. Epub 2012 Jun 5.

PMID:
22677511
12.

[Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].

Geinitz H, Zimmermann F, von Wedel E, Thamm R, Busch R, Feldmann HJ, Molls M.

Strahlenther Onkol. 2002 Jul;178(7):369-77. German.

PMID:
12163991
13.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C.

Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8.

PMID:
21440505
14.

Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer.

Takaha N, Okihara K, Kamoi K, Kimura Y, Yamada T, Kawauchi A, Kobayashi K, Yamazaki H, Nishimura T, Miki T.

Urol Int. 2011;87(1):28-34. doi: 10.1159/000324478. Epub 2011 Jun 23.

PMID:
21701133
15.

Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.

Malik R, Jani AB, Liauw SL.

Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1022-8. doi: 10.1016/j.ijrobp.2009.12.029. Epub 2010 May 24.

PMID:
20510547
16.
17.
18.

High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?

Cellini N, Pompei L, Fortuna G, Ammaturo MV, De Paula U, Luzi S, Mattiucci GC, Morganti AG, Digesù C, Rosetto ME, Palloni T, Petrongari MG, Gentile P, Deodato F, Valentini V.

Tumori. 2004 Mar-Apr;90(2):201-7.

PMID:
15237583
19.

Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.

Akakura K, Tsuji H, Suzuki H, Ichikawa T, Ishikawa H, Okada T, Kamada T, Harada M, Tsujii H, Shimazaki J.

Jpn J Clin Oncol. 2014 Apr;44(4):360-5. doi: 10.1093/jjco/hyu006. Epub 2014 Feb 28.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk